ASX:CU6Pharmaceuticals
Why Clarity Pharmaceuticals (ASX:CU6) Is Up 7.0% After AMPLIFY Trial Consent Completion And What's Next
Clarity Pharmaceuticals recently reported that its pivotal Phase III AMPLIFY trial for prostate cancer imaging agent 64Cu-SAR-bisPSMA has now consented more than the planned number of participants in the US and Australia, and has stopped new consents pending final enrolment confirmation.
This rapid completion of participant consent, building on data from earlier COBRA and Co-PSMA studies, underscores strong clinical interest in 64Cu-SAR-bisPSMA as Clarity pursues potential FDA approval for a...